Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting

Circulation

Volumn 102, Issue 24, 2000, Pages 2952-2958

  Marso, Steven P ^a   Bhatt, Deepak L ^b   Roe, Matthew T ^d   Houghtaling, Penny L ^b   Labinaz, Marino ^c   Kleiman, Neal S ^e   Dyke, Cornelius ^f   Simmoons, Maarten L ^g   Califf, Robert M ^d   Harrington, Robert A ^d   Topol, Eric J ^b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f Sanger Clinic   (United States)

^g ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Coronary disease; Glycoproteins; Grafting; Platelets

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; PLACEBO;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SURGICAL MORTALITY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0034642344     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.24.2952     Document Type: Article

References (17)

1. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1988
2. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes the PURSUIT Trial Investigators: Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
3. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina: Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
4. Symptoms (PRISM-PLUS) Study Investigators N, non-Q-wave myocardial infarction Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs, Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina
5. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy: Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VAN-QWISH) Trial Investigators
6. Validation and interdependence with patient-variables of the influence of procedural variables on early and late survival after CABG: K.U. Leuven Coronary Surgery Program
7. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge
8. Maintenance of clinical benefit at six-months in patients treated with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute coronary event
9. Coronary plaque disruption
10. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial: Thrombolysis in Myocardial Infarction
11. Platelet dysfunction during cardiopulmonary bypass surgery: With special reference to platelet membrane glycoproteins
12. The platelet in cardiopulmonary bypass
13. Cytokine responses to cardiopulmonary bypass with membrane and bubble oxygenation
14. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass
15. Inhibition of platelet adhesion during cardiopulmonary bypass reduces post-operative bleeding
16. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons
17. Tirofiban provides 'platelet anesthesia' during cardiopulmonary bypass in baboons